Ocata Therapeutics Licenses Induced Pluripotent Stem Cell Technology from Allele Biotechnology and Extends Leadership Position in Cell Therapy Capabilities

Ocata Therapeutics, Inc. , a leader in the field of Regenerative Ophthalmology, today announced that it has entered into a definitive agreement with Allele Biotechnology & Pharmaceuticals, Inc. of San Diego, CA to access Allele's proprietary technology for generating human induced pluripotent stem cells . "This agreement with Allele is part of our strategy to broaden our technology platform and increase our leadership in regenerative ophthalmology," said Paul Wotton Ph.D., President and CEO of Ocata.

http://ift.tt/1y1qNea